Copyright
©The Author(s) 2022.
World J Gastroenterol. Jan 28, 2022; 28(4): 479-496
Published online Jan 28, 2022. doi: 10.3748/wjg.v28.i4.479
Published online Jan 28, 2022. doi: 10.3748/wjg.v28.i4.479
Figure 8 Fibrinogen-like protein 2 deficiency impaired inflammatory cascade in response to lipopolysaccharide treatment of viral infection.
A: Immunoblot for fibrinogen-like protein 2 (Fgl2) and β-actin expression in wild-type (WT) BMDMs in response lipopolysaccharide (LPS) stimulation and murine hepatitis virus strain 3 (MHV-3) infection. B-E: Immunoblot for proteins panels from lysates of WT and Fgl2-/- BMDMs in response to LPS treatment and MHV-3 infection; B: MyD88, TRIF, IκBα, phosphorylated IκBα, phosphorylated p65 (S468) and IRF3, phosphorylated IRF3, and IRF7; C: p38, JNK, ERK and phosphorylated p38, JNK, ERK; D: Phosphorylated c-Raf, phosphorylated p65 (S276), acetyl p65 (lys310); E: BTK, and phosphorylated BTK (Y223), BTK (Tyr550). These experiments were repeated at least three times.
- Citation: Xiao F, Wang HW, Hu JJ, Tao R, Weng XX, Wang P, Wu D, Wang XJ, Yan WM, Xi D, Luo XP, Wan XY, Ning Q. Fibrinogen-like protein 2 deficiency inhibits virus-induced fulminant hepatitis through abrogating inflammatory macrophage activation. World J Gastroenterol 2022; 28(4): 479-496
- URL: https://www.wjgnet.com/1007-9327/full/v28/i4/479.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i4.479